Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.
There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.
Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...
ANAs are proteins produced by the immune system that mistakenly target the body's own cells, leading to tissue damage and ...
Having lupus may increase your risk of food allergies. And certain foods may trigger lupus flares. Learn more.
Zenas BioPharma's obexelimab demonstrates strong clinical results, but financial uncertainties remain. See more on ZBIO stock ...
Secukinumab is safe and effective over a 48-month period among patients with PsA, demonstrating sustained disease control and high drug retention rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback